ArticleFrontiers in pharmacology2026

Cost-effectiveness of disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial carcinoma in China.

Weicheng Lei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.